Bufotenin is classified as a Schedule I controlled substance according to the Criminal Code Regulations of the Government of the Commonwealth of Australia.  It is also listed as a Schedule 9 substance under the Poisons Standard (October 2015).  A schedule 9 drug is outlined in the Poisons Act 1964 as "Substances which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of the CEO." 
Apo-Perindopril Arginine 27 November 2017 Update 2 – additional batches being recalled Philips IntelliVue MX40 wearable patient monitor 24 November 2017 Update following revocation of suspension Infections associated with heater-cooler devices 15 November 2017 Update to statement regarding heater-cooler devices following recall action and suspension of LivaNova 3T heater-coolers Permobil powered wheelchairs - Corpus II seating system 17 October 2017 Recall for product correction - potential for injury due to breakage of the seating system
Serious arterial and venous thromboembolic (TE) events have been reported following administration of recommended doses of C1 Esterase Inhibitor (Human) products to patients with HAE. Risk factors may include presence of an indwelling venous catheter/access device; prior history of thrombosis; underlying atherosclerosis; use of oral contraceptives or certain androgens; morbid obesity; and immobility. Weigh benefits/risks before administering to patients with known risk factors for TE events and closely monitor such patients during and after BERINERT administration. TE events also have been reported with C1 Esterase Inhibitor (Human) products when used for unapproved indications at higher than recommended doses.